Zentalis Pharmaceuticals (ZNTL) Interest Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $51.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 12.17% year-over-year to $51.7 million in Q1 2026; TTM through Mar 2026 was $51.7 million, a 12.17% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 97.25% from the prior year.
• Interest Expenses rose to $51.7 million in Q1 2026 per ZNTL's latest filing, from $11000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $247.0 million in Q4 2024 and bottomed at $11000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $54.4 million (2025), against an average of $52.2 million.
• Across the five-year window, Interest Expenses surged 8077.09% in 2022 and slumped 100.0% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $74.2 million in 2022, then plunged by 91.38% to $6.4 million in 2023, then surged by 3759.77% to $247.0 million in 2024, then slumped by 100.0% to $11000.0 in 2025, then soared by 469881.82% to $51.7 million in 2026.
• Per Business Quant, the three latest ZNTL Interest Expenses figures stand at $51.7 million (Q1 2026), $11000.0 (Q4 2025), and $14.8 million (Q3 2025).